» Articles » PMID: 17552444

Evaluation of Client-specific Outcome Measures and Activity Monitoring to Measure Pain Relief in Cats with Osteoarthritis

Overview
Date 2007 Jun 8
PMID 17552444
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There are no validated systems for measuring pain from osteoarthritis in cats.

Hypothesis: Owner subjective assessments and an activity monitor (AM) can be used to detect pain in cats with osteoarthritis and to assess efficacy of treatments.

Animals: Thirteen cats older than 10 years old, with owner-assessed decreases in activity, painful arthritic joints, and clinically normal blood work were included and evaluated for 3 weeks.

Methods: A collar-mounted AM measured activity and a client-specific outcome measure (CSOM) questionnaire characterized the severity of impairment. Overall global quality of life was also evaluated for each treatment. In weeks 2 and 3, meloxicam (0.1 mg/kg, day 1; 0.05 mg/kg, days 2-5) or a placebo was administered in a blinded, randomized, cross-over manner to test the assessment systems.

Results: The cats had a median of 4 arthritic appendicular joints. Activity counts for the week when cats (complete data on activity; n=9) were administered meloxicam were significantly higher than at baseline (P = .02) but not after placebo (P = .06). Baseline activity counts were not significantly different from placebo (P = .6). The CSOM data (n=13) showed that owners considered their cats to be more active on meloxicam compared with baseline (P = .001) and placebo (P < .004), and more active on placebo than at baseline (P < .01). Global quality of life improved significantly with meloxicam (P < .042).

Conclusions And Clinical Importance: Both an AM and a CSOM system can detect behavior associated with pain relief in cats that are arthritic. Objective activity data might allow subjective assessment systems to be validated for use in clinical studies.

Citing Articles

Relationship between Feline Knee Joint Osteoarthritis and Bone Mineral Density Quantified Using Computed Tomography and Computed Digital Absorptiometry.

Bonecka J, Turek B, Jankowski K, Borowska M, Jasinski T, Smyth G Animals (Basel). 2024; 14(17).

PMID: 39272400 PMC: 11394321. DOI: 10.3390/ani14172615.


The use of platelet rich plasma in the treatment of degenerative joint disease in cats: an exploratory case series.

Huntingford J, Looney A, Johnson J, Miller L Front Vet Sci. 2024; 11:1394055.

PMID: 38863451 PMC: 11165359. DOI: 10.3389/fvets.2024.1394055.


2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats.

Taylor S, Gruen M, KuKanich K, Lascelles B, Monteiro B, Sampietro L J Feline Med Surg. 2024; 26(4):1098612X241241951.

PMID: 38587872 PMC: 11103309. DOI: 10.1177/1098612X241241951.


Concurrent Validation of MI-CAT(V), a Clinical Metrology Instrument for Veterinarians Assessing Osteoarthritis Pain in Cats, through Testing for Firocoxib Analgesic Efficacy in a Prospective, Randomized, Controlled, and Blinded Study.

Delsart A, Otis C, Leung V, Labelle E, Moreau M, Frezier M Animals (Basel). 2024; 14(5).

PMID: 38473097 PMC: 10931368. DOI: 10.3390/ani14050711.


Development and Preliminary Validation of an Equine Brief Pain Inventory for Owner Assessment of Chronic Pain Due to Osteoarthritis in Horses.

Howard D, Lancaster B, de Grauw J Animals (Basel). 2024; 14(2).

PMID: 38254349 PMC: 10812429. DOI: 10.3390/ani14020181.